In prostate cancer, serum PSA lacks metastasis specificity—some mCRPC patients maintain normal levels —but high PSA (>15.275ng/ml) predicts 99mTc-MDP-detectable bone metastases. Here, KLK3 is linked to prostate carcinoma.